Loading stock data…
ALKS
$33.38-0.33 (-0.98%)
Market ClosedLast close May 1
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alkermes plc in the Healthcare sector is trading at $33.38. The stock is currently 8% below its 52-week high of $36.48, remaining 10.6% above its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why ALKS maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$33.38
Potential Downside
7.5%
Whystock Fair Value$30.88
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus17 analysts
Mean target$44.53+33.4%
Range$30.00 – $58.00
Fundamentals
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.62B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
23.59
Beta
Defensive asset. Lower volatility than the S&P 500.
0.39
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
19.15%
Volume
Today's trading volume
1.14M
Recent News
Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
PCRX Q1 earnings miss estimates as rising costs weigh on profit, but revenues top expectations on Exparel demand and growth from Zilretta and iovera.
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Believe Alkermes (ALKS) Could Rally 29.14%: Here's is How to Trade
The consensus price target hints at a 29.1% upside potential for Alkermes (ALKS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Did New Alixorexton Data and LYBALVI Outcomes Just Shift Alkermes' (ALKS) Neuroscience Investment Narrative?
Alkermes recently highlighted new data from its Vibrance-1 phase 2 study of alixorexton in narcolepsy type 1, showing clinically meaningful improvements in wakefulness, cognition and fatigue over 13 weeks with a favorable safety profile, alongside growing evidence for LYBALVI’s impact on negative symptoms in schizophrenia. The combination of advancing an orexin 2 receptor agonist with Breakthrough Therapy designation and publishing longer-term LYBALVI outcomes may influence how investors...